Australian rollout brings innovative medication-liquefying technology closer to patients, carers and healthcare professionals
Medasyst is proud to announce its rollout across the 950 independent pharmacies Australia-wide within the IPA Network, bringing its innovative medication-liquefying technology closer to the patients, carers and families who need it.
Medasyst selected IPA because of its independence, strong connection to community pharmacy and its close ties with customers, with a shared commitment to supporting individuals in their health and wellness.
The national rollout is designed to encourage patients and carers who struggle with swallowing medications to speak with their pharmacist or doctor about whether their medication can be tailored into a liquid form using Medasyst technology.
Difficulty swallowing medication can be a significant challenge for people living with long-term health conditions, disability, age-related swallowing difficulties and other circumstances where conventional tablets may be difficult to administer. Medasyst provides a solution that removes the need for problematic manual crushing of medications, a process that can be difficult, time-consuming and may result in loss of dose or difficulties with administration.
Medasyst CEO Georgios Mihos said the partnership with IPA represents an important step in bringing the technology into the heart of Australian communities.
“We are delighted with our association with IPA nationally, as it further embeds our revolutionary Medasyst technology into the community and gets it into the hands of the people that need it — the long-term unwell and the carers often having to crush medications by hand.”
Mihos said the impact on carers could be particularly significant.
“One lady recently spoke of having to crush medications for her son, who is now 36 but has been highly dependent since birth. She requires cortisone injections for her wrists. With Medasyst, it’s a game changer as the machine takes all the hard work out.”
“We are delighted to work with the IPA pharmacists and their customers,” Mihos said.
Mihos said Medasyst’s role extends beyond the patient and pharmacy, requiring collaboration across the broader healthcare network.
“We recognise we have to work not just with the consumer, but everyone in the healthcare network, including carers, speech pathologists, doctors and pharmacy.”
He said the partnership with IPA further strengthens the case for solutions that address medication non-adherence and the significant waste associated with medications that are not taken as prescribed.
“Pharmacy further legitimises what is a very clever solution to the $500 billion worth of waste due to non-adherence of medications,” he said.
An IPA spokesperson said Medasyst was welcomed into the network because of the clear need among a range of IPA customers.
“Medasyst was accepted into the range of products as we could see the direct need by certain customers who struggle to swallow medications or are on PEG feeds,” the spokesperson said.
“It allows us to offer another level of service to our customers and into our communities, including aged care.”
Supporting conversations between patients and healthcare professionals
As Medasyst products roll out across Australia, patients and carers are being encouraged to have a conversation with their pharmacist or doctor if swallowing medication has become difficult.
Medication should not be altered without appropriate advice from a healthcare professional, as not all medicines are suitable for crushing or conversion into a liquid formulation. Pharmacists and prescribers can assess individual medications and determine an appropriate approach for each patient.
The Medasyst rollout through IPA represents another step towards making medication administration easier for patients and carers while strengthening the role of community pharmacies in delivering personalised healthcare solutions.
About Medasyst
Medasyst is an innovative medication administration technology designed to support the preparation of suitable medications into a liquefied form, helping address challenges associated with swallowing and medication administration. Its technology is designed to remove the need for problematic manual crushing and simplify the process for patients, carers and healthcare professionals.